The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review

被引:45
作者
Asghar, Waheed [1 ]
Jamali, Fakhreddin [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2E1, Canada
关键词
Non-steroidal anti-inflammatory drugs (NSAIDs); Meloxicam; Cardiovascular risk; Systematic review; Vascular; Myocardial; Renal; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LONG-TERM USE; CARDIOVASCULAR EVENTS; RHEUMATOID-ARTHRITIS; GENERAL-PRACTICE; INCIDENCE RATES; HEART-FAILURE; INHIBITORS; INFARCTION; ROFECOXIB;
D O I
10.1007/s10787-014-0225-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of cardiovascular (CV) and renal incidences, especially at higher doses and upon long term use. However, the available reports are criticized for lack of specificity, grouping of vastly different outcomes together and ignoring the heterogeneity among NSAIDs. In this systematic review, we are reporting CV/renal risks associated with meloxicam, stratified into myocardial, vascular, renal risk categories, to address the differential nature of NSAIDs effects on different body systems. We are also reporting composite CV/renal risk to present overall risk associated with various covariates. We searched the online healthcare databases for observational studies or randomized controlled trials, reporting myocardial or all-cause mortality outcome (> 90 days exposure) and/or vascular/renal outcomes (any exposure) after meloxicam use, published until April 2014. The combined odd ratio values (OR'; 95 % CI) were calculated using the random effect inverse variance model. We found 19 eligible studies out of 2,422 reports. Meloxicam demonstrated a low increase in composite risk (OR' 1.14; CI 1.04-1.25) which was mainly vascular in nature (OR' 1.35; CI 1.18-1.55] as it did not elevate myocardial (OR' 1.13; CI 0.98-1.32) or renal (OR', 0.99; CI 0.72-1.35) risks. Relative to meloxicam, other NSAIDs increased the composite risk, in a dose-dependent fashion, in the following order: rofecoxib > indomethacin > diclofenac > celecoxib > naproxen > ibuprofen. OR' was also influenced by type of disease and the comparator used, and acetylsalicylic acid. NSAIDs are heterogeneous in increasing CV/renal risks. The low increased risk associated with meloxicam is mainly vascular in origin.
引用
收藏
页码:1 / 16
页数:16
相关论文
共 70 条
[1]  
[Anonymous], 2010, International statistical classification of diseases and related health problems, 10th revision
[2]  
[Anonymous], 2003, MetaAnalysis Of Controlled Clinical Trials
[3]   Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association [J].
Antman, Elliott M. ;
Bennett, Joel S. ;
Daugherty, Alan ;
Furberg, Curt ;
Roberts, Harold ;
Taubert, Kathryn A. .
CIRCULATION, 2007, 115 (12) :1634-1642
[4]  
Arvind C, 2004, APLAR J RHEUMATOL, V7, P108
[5]   Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis [J].
Balmaceda, Casilda M. .
BMC MUSCULOSKELETAL DISORDERS, 2014, 15
[6]   Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials [J].
Bhala, N. ;
Emberson, J. ;
Merhi, A. ;
Abramson, S. ;
Arber, N. ;
Baron, J. A. ;
Bombardier, C. ;
Cannon, C. ;
Farkouh, M. E. ;
FitzGerald, G. A. ;
Goss, P. ;
Halls, H. ;
Hawk, E. ;
Hawkey, C. ;
Hennekens, C. ;
Hochberg, M. ;
Holland, L. E. ;
Kearney, P. M. ;
Laine, L. ;
Lanas, A. ;
Lance, P. ;
Laupacis, A. ;
Oates, J. ;
Patrono, C. ;
Schnitzer, T. J. ;
Solomon, S. ;
Tugwell, P. ;
Wilson, K. ;
Wittes, J. ;
Baigent, C. ;
Adelowo, O. ;
Aisen, P. ;
Al-Quorain, A. ;
Altman, R. ;
Bakris, G. ;
Baumgartner, H. ;
Bresee, C. ;
Carducci, M. ;
Chang, D-M. ;
Chou, C-T. ;
Clegg, D. ;
Cudkowicz, M. ;
Doody, L. ;
El Miedany, Y. ;
Falandry, C. ;
Farley, J. ;
Ford, L. ;
GarciLosa, M. ;
Gonzalez-Ortiz, M. ;
Haghighi, M. .
LANCET, 2013, 382 (9894) :769-779
[7]   Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism [J].
Biere-Rafi, Sara ;
Di Nisio, Marcello ;
Gerdes, Victor ;
Porreca, Ettore ;
Souverein, Patrick ;
de Boer, Anthonius ;
Buller, Harry ;
Kamphuisen, Pieter .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (06) :635-642
[8]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[9]   Renal effects of COX-2-selective inhibitors [J].
Brater, DC ;
Harris, C ;
Redfern, JS ;
Gertz, BJ .
AMERICAN JOURNAL OF NEPHROLOGY, 2001, 21 (01) :1-15
[10]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102